Published: June 18, 2021 | Tags: Lineage, Option Agreement, Amasa Therapeutics, Clinical-Grade Hystem
BioNTech Reports First Patient Dosing in P-II Clinical Trial of BNT111 to Treat Advanced Melanoma
Published: June 18, 2021 | Tags: BioNTech, P-II, Clinical Trial, BNT111, Advanced Melanoma
CytoReason Collaborates with Sanofi to Initiate its Project Utilizing AI Technology for Asthma
Published: June 18, 2021 | Tags: CytoReason, Project, Utilizing, Sanofi, AI Technology, Asthma
Published: June 18, 2021 | Tags: BeiGene, P-III, AdvanTIG-302 Trial, Ociperlimab, BGB-A1217, Tislelizumab, BGB-A317 Non-Small Cell Lung Cancer
Kite Enter into a Partnership with Shoreline Biosciences to Develop Novel Allogeneic Cell Therapies
Published: June 18, 2021 | Tags: Kite, Shoreline Biosciences, Develop, Novel Allogeneic Cell Therapies
Published: June 18, 2021 | Tags: Biogen, P-III, TOPAZ-1 Study, BIIB059, Systemic Lupus Erythematosus
Published: June 17, 2021 | Tags: Biogen, Gosuranemab, BIIB092, Primary Endpoint, P-II, TANGO Study Alzheimer Disease
Atea Pharma Secures $50M Milestone Payment with Roche in the Development of AT-527 for COVID-19
Published: June 17, 2021 | Tags: Atea Pharma, Milestone Payment, License Agreement, Roche, AT-527
Published: June 17, 2021 | Tags: Blueprint Medicines, Ayvakit, avapritinib, FDA, Approval, Advanced Systemic Mastocytosis
Published: June 17, 2021 | Tags: CureVac, Second Interim Analysis, P-llb/lll HERALD Trial, CVnCoV, COVID-19
Published: June 17, 2021 | Tags: MannKind, United Therapeutics, US, FDA, Acceptance, NDA, Priority Review, Tyvaso DPI, PAH, PH-ILD
Published: June 17, 2021 | Tags: Pfizer, Tofacitinib, STOP-COVID Study, COVID-19 Pneumonia, NEJM
Published: June 16, 2021 | Tags: Lundbeck, Vyepti, eptinezumab-jjmr, RELIEF Study, Migraine, JAMA
Organicell Reports Results of Expanded Access Trial for Zofin to Treat Mild to Moderate COVID-19
Published: June 16, 2021 | Tags: Organicell, Expanded Access Trial, Zofin, COVID-19
Published: June 16, 2021 | Tags: Regeneron, REGEN-COV, Casirivimab, Imdevimab, P-III, RECOVERY Trial, COVID-19
Gilead and Jounce’s JTX-1811 Receives US FDA’s IND Clearance for Cancer Immunotherapies
Published: June 16, 2021 | Tags: Gilead, Jounce, JTX-1811, US, FDA, IND, Clearance, Cancer Immunotherapies
Published: June 16, 2021 | Tags: Linnaeus Therapeutics, Clinical Collaboration, Merck, LNS8801, Keytruda, Advanced Cancer
Innovent Reports First Patient Dosing in P-II Clinical Trial for the Treatment of Obesity in China
Published: June 16, 2021 | Tags: Innovent, P-II, Clinical Trial, Obesity, China
Sage and Biogen Report Results of Zuranolone in P-III WATERFALL Study for Major Depressive Disorder
Published: June 15, 2021 | Tags: Sage, Biogen, Zuranolone, P-III, WATERFALL Study, Depressive Disorder
Published: June 15, 2021 | Tags: AstraZeneca, AZD7442, P-III, STORM CHASER Study, Symptomatic COVID-19
Published: June 15, 2021 | Tags: BeiGene, Tislelizumab, Asieris, APL-1202, US, FDA, IND, Approval, MIBC
Published: June 15, 2021 | Tags: AstraZeneca, AZD7442, P-III, STORM CHASER Study, Symptomatic COVID-19
Novavax’s COVID-19 Vaccine Demonstrates 90.4% Efficacy in P-III PREVENT-19 Study
Published: June 15, 2021 | Tags: Novavax, COVID-19 Vaccine, 90.4% Efficacy, P-III, PREVENT-19 Study
Biogen’s BIIB111 Fails to Meet its Primary Endpoint in P-III STAR Study for Choroideremia
Published: June 15, 2021 | Tags: Biogen, BIIB111, Primary Endpoint, P-III, STAR Study, Choroideremia
GSK Signs an Agreement with iTeos to Develop and Commercialize EOS-448 for Patients with Cancer
Published: June 14, 2021 | Tags: GSK, iTeos Therapeutics, Co-Develop, Commercialize, EOS-448, Cancer
Published: June 14, 2021 | Tags: Kite, Yescarta, axicabtagene ciloleucel, P-II, ZUMA-5 Trial, R/R Follicular Lymphoma, EHA 2021
Published: June 14, 2021 | Tags: AbbVie, Imbruvica, ibrutinib, Venclexta, Venclyxto, venetoclax, P-III, GLOW Study, CLL, SLL, EHA 2021
Published: June 14, 2021 | Tags: Janssen, Darzalex, daratumumab, P-III, MAIA Study, Multiple Myeloma, EHA 2021
Published: June 14, 2021 | Tags: Celltrion Healthcare, Truxima, biosimilar, rituximab, Diffuse Large B-Cell Lymphoma, EHA 2021
Published: June 14, 2021 | Tags: Sanofi, Sutimlimab, Part A, P-III, CADENZA Trial, Hemolysis, Cold Agglutinin Disease, EHA 2021
Related Post: PharmaShots Weekly Snapshots (June 07 – 11, 2021)
The post PharmaShots Weekly Snapshots (June 14 – 18, 2021) first appeared on PharmaShots.